Companies /Healthcare

Biodesix Inc

NASDAQ: BDSX Diagnostics & Research
$28.81
▲ $0.25 (+0.88%) today
Markets closed · 7:47pm ET
Today · % change

Fundamentals

Market Cap
$301.3M
Profit Margin
-27.0%
Revenue (TTM)
$102.9M
EPS (TTM)
$-3.21
52-Week Range
$5 – $31
Street Target
$34.00

About Biodesix

Biodesix Inc is a Boulder, Colorado-based company specializing in diagnostic solutions, particularly for lung cancer. It offers a range of blood-based tests, such as Nodify XL2 and Nodify CDT, part of its Nodify Lung Nodule Risk Assessment strategy, designed to evaluate lung cancer risk and assist in treatment decisions. The company also provides GeneStrat ddPCR, VeriStrat, and GeneStrat NGS tests for lung cancer diagnosis, focusing on tumor mutations and immune system status. Additionally, Biodesix collaborates with Bio-Rad Laboratories to offer COVID-19 testing solutions, including the Bio-Rad SARS-CoV-2 ddPCR test. It also engages in the discovery, development, and commercialization of companion diagnostics for biopharmaceutical companies.

BDSX Coverage